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Abstract 
 
HER2-targeted therapy is considered effective for KRAS codon 12/13 wild-type, HER2-
positive metastatic colorectal cancer (CRC). In general, HER2 status is determined by the use 
of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). 
Comprehensive genomic sequencing (CGS) enables the detection of gene mutations and copy 
number alterations including KRAS mutation and HER2 amplification; however, little is 
known about the utility of CGS for detecting HER2-positive CRC. To assess its utility, we 
retrospectively investigated 201 patients with stage I–IV CRC. The HER2 status of the 
primary site was assessed using IHC and FISH, and HER2 amplification of the primary site 
was also assessed using CGS, and the findings of these approaches were compared in each 
patient. CGS successfully detected alterations in 415 genes including KRAS codon 12/13 
mutation and HER2 amplification. Fifty-nine (29%) patients had a KRAS codon 12/13 
mutation. Ten (5%) patients were diagnosed as HER2-positive because of HER2 IHC 3+, and 
the same 10 (5%) patients had HER2 amplification evaluated using CGS. The results of 
HER2 status and HER2 amplification were completely identical in all 201 patients (P < 
0.001). Nine of the 10 HER2-positive patients were KRAS 12/13 wild-type and were 
considered possible candidates for HER2-targeted therapy. CGS has the same utility as IHC 
and FISH for detecting HER2-positive patients who are candidates for HER2-targeted 
therapy, and facilitates precision medicine and tailor-made treatment. 
 
 
Word count of the abstract: 226 words 
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Highlights 
 
 HER2-targeted therapy is possibly effective for HER2-positive colorectal cancer. 
 Generally, HER2 status is determined by immunohistochemistry (IHC). 
 HER2 amplification can be also detected by comprehensive genomic sequencing (CGS). 
 This study showed that the results of IHC and CGS were completely identical. 
 CGS has the same utility as IHC for detecting HER2-positive colorectal cancer. 
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Introduction 
 
HER2, a member of the human epidermal growth factor receptor (HER) family, is a plasma 
membrane protein with intrinsic tyrosine kinase activity [1]. In contrast to other HER family 
members, HER2 is a receptor with no ligand; HER2 protein activation depends directly on its 
dimerization with another HER2 monomer or with a monomer of another HER family 
member, such as HER3 [2, 3]. After dimerization, the most important signaling pathways, 
such as the mitogen-activated protein kinase (MAPK) and PI3K pathways, are activated by 
HER2, resulting in cell duplication and regulation of apoptosis [4]. HER2 signal transduction 
can be dysregulated via different mechanisms. HER2 overexpression, generally resulting 
from HER2 gene amplification [5, 6], is one of the main causes of the constitutive activation 
of HER2 signal transduction in many cancers [7]. 
 
HER2 overexpression and/or amplification are associated with carcinogenesis, poor 
prognosis, and may also predict the response to chemotherapy [7]. Under the rationale for 
using anti-HER2 targeted approaches to block its oncogenic effects, anti-HER2 monoclonal 
antibodies have been designed for HER2-positive tumors. Trastuzumab is a monoclonal 
antibody that recognizes the extracellular portion of the HER2 receptor, and once bound, it 
completely inhibits HER2 activity [8]. Today, trastuzumab treatment is the standard care for 
HER2-positive breast [9] and gastric cancers [10]. In addition to breast and gastric cancers, 
preclinical models and clinical trials are underway to assess the efficacy of HER2-targeted 
therapy for patients with colorectal cancer (CRC) [11]. Several studies reported the incidence 
of HER2-positive cases and its clinical significance in CRC [12-19], and the use of 
trastuzumab for HER2-positive cases is recognized as a promising treatment strategy for 
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KRAS wild-type metastatic CRC [19-21]. Recently, the HERACLES trial demonstrated the 
efficacy of dual-targeted therapy with trastuzumab and lapatinib for KRAS codon 12/13 wild-
type and HER2-positive CRC [22]. Hence, both KRAS mutation and HER2 status should be 
evaluated to select candidates for HER2-targeted therapy in CRC. 
 
In current histopathology, the HER2 status of breast and gastric cancer is determined by 
immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) [23, 24]; likewise, 
the HER2 status of CRC is usually evaluated by IHC and FISH [22]. Conversely, by utilizing 
next-generation sequencing technology, projects such as The Cancer Genome Atlas (TCGA) 
have profiled genomic changes in several cancers including CRC [25]. Comprehensive 
genomic sequencing (CGS) can detect gene mutations and copy number alterations in a 
single assay, including KRAS mutation and HER2 amplification. However, it is not clear 
whether CGS has the same diagnostic value as IHC and FISH for detecting HER2-positive 
CRC. Therefore, the aim of this study was to clarify the utility of CGS for detecting HER2-
positive CRC.  
 
Materials and methods 
 
Patients 
 
A total of 201 patients diagnosed with stage I - IV CRC according to AJCC 7th edition [26] 
who performed primary tumor resection between 2009 and 2015 at Niigata University 
Medical and Dental Hospital or Niigata Cancer Center Hospital were enrolled. Patients with 
familial adenomatous polyposis or inflammatory bowel disease were excluded. None of the 
patients had received neoadjuvant radiation or HER2-targeted therapy. This retrospective 
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study was performed in accordance with the Helsinki Declaration, and the Ethics Committee 
of the School of Medicine, Niigata University approved the study protocol. 
 
Pathological evaluation of HER2 status 
 
Resected specimens were fixed immediately in 10% buffered formalin for 24 h, and the entire 
tumor was cut into step-wise sections and embedded in paraffin. Each section was examined 
with hematoxylin and eosin (HE) staining, and the archives were reviewed for each case to 
select one cross-section with the most invasion. The corresponding paraffin blocks were re-
cut, making 4-m thick slices, and 3 serial sections were assigned for HE staining, anti-HER2 
staining, and a negative control. HER2 status was determined according to the HERACLES 
diagnostic criteria: HER2-positive status was defined as tumors with a 3+ HER2 score in 
more than 50% of cells by IHC or with a 2+ HER2 score and a HER2:CEP17 ratio higher 
than 2.0 in more than 50% of cells by FISH [22]. 
 
IHC for evaluating HER2 status 
 
Specimen slides were deparaffinized, followed by dehydration with ethanol. The sections 
were washed 3 times with phosphate-buffered saline for 5 min. The sections were digested 
with 0.03 U/g protease, diluted with 0.05 M Tris-HCl pH 7.6, at room temperature for 5 min 
(protease: type EX No. P3111; SIGMA Aldrich Corp., St. Louis, MO). After blocking 
nonspecific reactivity with 3% H2O2 for 5 min, an anti-HER2 monoclonal antibody (SV2-
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61 Nichirei Biosciences, Inc., Tokyo, Japan) was applied at 5 mg/mL (diluted with 0.5% 
bovine serum albumin/phosphate-buffered saline) at room temperature for 30 min. Then, the 
sections were incubated with Histofine Simple Stain MAX PO (M) (Nichirei Biosciences, 
Inc.) at room temperature for 30 min, followed by incubation for 10 min with a DAB kit 
(Nichirei Biosciences, Inc.), and the sections were counterstained with hematoxylin. Positive 
tissue controls were included in each run; these tissues were breast tumors with known HER2 
protein overexpression and HER2 gene amplification [27]. 
 
FISH for evaluating HER2 status 
 
Specimen slides were deparaffinized, followed by dehydration with ethanol. Each slide was 
treated with a Vysis Paraffin Pretreatment Kit (Abbott Molecular, Des Plaines, IL). After 
pretreatment, the resulting specimen DNA was denatured and the slides were dehydrated in 
serial ethanol solutions and subsequently allowed to hybridize with the PathVysion (Abbott 
Molecular) probe mixture. Following hybridization, excess and unbound probe was removed 
by a series of washes, and the chromosomes and nuclei were counterstained with the DNA-
specific stain 4′,6 diamidino-2-phenylindole, which fluoresces blue under UV illumination. 
Hybridization of the HER2/neu and CEP 17 DNA probes was viewed using a fluorescence 
microscope equipped with appropriate excitation and emission filters, allowing visualization 
of the orange and green fluorescent signals and the blue counterstained chromosomes and 
nuclei [28]. 
 
CGS of primary sites 
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Archival tissue in the form of formalin-fixed, paraffin-embedded tumor or unstained tissue 
sections obtained during primary tumor resection were used for CGS, and HER2 
amplification, HER2 mutation, and KRAS exon 2 (codon 12 and 13) mutation were evaluated. 
An independent pathologist evaluated tumor content on HE-stained slides for each study 
sample to ensure >50% tumor content was present. Where applicable, unstained slides were 
macro-dissected to enrich for tumor content and DNA was extracted using a BioStic FFPE 
Tissue DNA Isolation Kit (Mo Bio Laboratories, Inc., CA). All sample preparation, CGS, and 
analytics were performed in a CLIA/CAP-accredited laboratory (KEW, Cambridge, MA). 
DNA (50–150 ng) fragment libraries were prepared and enriched for the 415 gene panel with 
CancerPlex (KEW, Cambridge, MA) [29]. CancerPlex is a clinically validated 415 gene 
panel enriched for coding regions and selected introns of genes with a known association to 
cancer. Sequencing was performed on the Illumina MiSeq and NextSeq platforms with an 
average 500× sequencing depth. Genomic data were then processed through a proprietary 
bioinformatics platform and knowledgebase to identify multiple classes of genomic 
abnormalities including single nucleotide substitutions (SNPs), small insertions/deletions 
(indels), copy number variation, and translocations. A threshold of 10% allelic fraction was 
used for SNPs and indels and thresholds of >2.5-fold (gain) and 0.5-fold (loss) were used. 
 
HER2 status and other clinicopathological characteristics 
 
To analyze the relationship between HER2 status and other clinicopathological 
characteristics, 11 clinicopathological variables were examined in all 201 patients: age (<65 
vs. ≥65 years), sex (male vs. female), tumor location (right vs. left), tumor size (<50 vs. ≥50 
mm), T category (T1, 2 vs. T3, 4), histopathological grading (G1, 2 vs. G3), lymphatic 
invasion (absence vs. presence), venous invasion (absence vs. presence), N category (N0 vs. 
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N1, 2), M category (M1a vs. M1b), KRAS exon 2 (codons 12 and 13) mutation (wild-type vs. 
mutant), NRAS exon 2 (codons 12 and 13) mutation (wild-type vs. mutant), and BRAF V600E 
mutation (wild-type vs. mutant). Histopathological markers associated with deficiency of 
mismatch repair gene, such as medullary type, mucinous type, Crohn-like lymphoid reaction, 
and tumor infiltrating lymphocytes were analyzed by reported method [30]. A total of 110 of 
201 patients were randomly selected and evaluated for MutL homologue 1 (MLH1)/MutS 
homologue 2 (MSH2) status using immunohistochemical stainings. The primary antibodies 
were MLH1 (1:50; BD Biosciences PharMingen, San Diego, CA) and MSH2 (1:50; Leica 
Microbiosystems, Tokyo, Japan). 
 
Comparison of HER2 status between primary and paired metastatic sites 
 
In the present study, 45 of the 201 patients underwent metastasectomy. The following 
metastatic sites were evaluated for HER2 status by the same methods as for the primary site 
[22]: liver (30 patients), lung (4 patients), ovary (3 patients), peritoneum (2 patients), brain (2 
patients), omentum (2 patients), para-aortic lymph node (1 patient), and bone (1 patient). 
 
Statistical analysis 
 
Statistical analyses were performed with IBM SPSS Statistics 22 (IBM Japan, Inc., Tokyo, 
Japan). Fisher’s exact test was used to evaluate the associations between HER2 status and 
HER2 amplification evaluated using CGS, and HER2 status and HER2 mutation evaluated 
using CGS. HER2 status and each clinicopathological variable, and HER2 status between the 
primary site and metastatic site was also evaluated by Fisher’s exact test. P-values less than 
0.05 were considered statistically significant. 
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Results 
 
IHC and FISH for HER2 status at the primary site 
 
Ten patients were HER2 IHC 3+ in more than 50% of the cancer area (Fig. 1A, B), and 2 
patients were HER2 IHC 3+ in less than 50% (Fig. 1C, D). Fifteen patients were HER2 IHC 
2+; however, there was no patient with IHC 2+ and a HER2:CEP17 ratio higher than 2.0 in 
more than 50% of cells by FISH. Hence, 10 of the 201 (5%) patients with HER2 IHC 3+ in 
more than 50% of the cancer area were diagnosed as HER2-positive by the HERACLES 
diagnostic criteria. 
 
Association between HER2 status and HER2 amplification evaluated using CGS 
 
CGS successfully detected alterations in 415 genes including KRAS codon 12/13 mutation 
and HER2 amplification. Forty-nine of the 201 (29%) patients had a KRAS codon 12/13 
mutation. Ten of the 201 (5%) patients had a HER2 amplification. The result of HER2 
amplification evaluated using CGS and that of HER2 status evaluated using IHC were 
completely identical in all 201 patients (P < 0.001) (Table 1) (Table 2). Nine of the 10 HER2-
positive patients were KRAS 12/13 wild-type, who were considered to be possible candidates 
for HER2-targeted therapy (Fig. 2).  
 
Association between HER2 status and HER2 mutation evaluated using CGS 
 
CGS also detected HER2 mutations (V308M, S310Y, R647K, R678Q, and A879delinsAE) in 
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6 of 201 (3%) patients. Among the 6 patients, only 1 patient had both HER2 mutation 
(S310Y) and HER2 amplification, and the patient showed HER2 positive (IHC 3+) (Table 2). 
No significant association was observed between HER2 status and HER2 mutation (P = 
0.267). 
 
HER2 status and other clinicopathological characteristics 
 
There was no significant association between HER2 status and other clinicopathological 
characteristics (Table 3). 
 
Comparison of HER2 status between the primary and paired metastatic sites 
 
At the metastatic sites, 3 of 45 (7%) patients were HER2-positive. Comparing between the 
primary and metastatic sites, 44 of the 45 (98%) patients showed a concordant HER2 status 
(Table 4). Focusing on the 4 patients with a positive HER2 status at the primary site, 3 of 
these patients were HER2-positive at the metastatic site (Fig. 3); however, the remaining 
patient was HER2-negative at the metastatic site: IHC score 3+ (100% area) at the primary 
site and IHC 0 at the metastatic site (para-aortic lymph node). 
 
Discussion 
 
In the present study, we showed two main results regarding the utility of CGS for detecting 
HER2-positive CRC patients. First, CGS successfully detected HER2 amplification in 10 of 
201 (5%) patients. Second, the result for HER2 amplification evaluated using CGS and that 
for HER2 status evaluated using IHC and FISH were completely identical in all 201 patients. 
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These results imply that CGS can reliably detect HER2-positive CRC patients, who are 
candidates for HER2-targeted therapy.  
 
HER2-targeted therapy is considered a promising strategy for KRAS wild-type metastatic 
CRC [19-21], and the evaluation of HER2 status and KRAS mutation is necessary to select 
candidates for HER2-targeted therapy. Recently, the HERACLES trial revealed the efficacy 
of dual targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 
12/13 wild-type, HER2-positive metastatic CRC [22]. In the trial, HER2 status was evaluated 
using IHC and FISH, and HER2-positivity was defined using the CRC-specific HERACLES 
diagnostic criteria [22]. In the present study, we also assessed HER2 status according to the 
HERACLES diagnostic criteria. Conversely, CGS can detect multiple gene alterations 
including KRAS codon 12/13 mutation and HER2 amplification in a single assay. However, to 
date, no study has investigated the concordance of HER2-positivity between HER2 status and 
HER2 amplification detected by CGS. In the current study, we tested the utility of CGS for 
detecting HER2-positive CRC using a 415-gene panel designed for solid tumors. 
 
The ultimate goal of cancer genome profiling is to enable precision medicine, i.e., the 
tailoring of treatments based on the unique genomic changes of each patient’s individual 
tumor. In CRC, gene mutations in the MAPK pathway, such as KRAS, NRAS, and BRAF, are 
important benchmarks to decide treatment strategies for patients with metastatic CRC. The 
National Comprehensive Cancer Network guidelines state that all patients with metastatic 
CRC should have tumor tissue genotyped for KRAS, NRAS, and BRAF mutations [31]. 
Patients with any known KRAS or NRAS mutation should not be treated with EGFR-targeted 
therapy such as cetuximab and panitumumab [32]. In the present study, we successfully 
detected alterations in 415 genes including KRAS, NRAS, and BRAF mutations and HER2 
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amplification and mutation, which implies that CGS cannot only detect candidates for EGFR-
targeted therapy but can also identify those for HER-2 targeted therapy in a single assay. 
 
TCGA project found that 4% of CRC patients have HER2 mutations [25]. However, to date, 
HER2 mutations in CRC has not been fully studied, and it is an open question as to whether 
HER2 mutations are clinically important in CRC. Kavuri et al. reported that HER2 mutations 
S310F, L755S, V777L, V842I, and L866M are activating mutations in CRC, and the HER2 
activating mutations may be drug targets for the treatment of CRC [33]. In the present study, 
we identified 6 of 201 (3%) patients with HER2 mutations (V308M, S310Y, R647K, R678Q, 
and A879delinsAE), that require further investigation to determine their oncogenicity. 
Among the 6 patients with HER2 mutations, only 1 patient had both HER2 mutation and 
HER2 amplification, who interestingly showed HER2 positive (IHC3+). We speculate that 
patients with both HER2 mutation and HER2 amplification may be candidates for HER2-
targeted therapy when the patients show HER2 positive using IHC/FISH. In addition to 
HER2 amplification, future studies might have to focus on the significance of HER2 
mutations in CRC, and clarify whether HER2 mutations are drug targets for CRC treatment. 
 
In this study, we showed the utility of CGS for detecting HER2-positive patients, who are 
candidates for HER2-targeted therapy; however, HER2-positive patients do not always 
demonstrate a favorable response to this treatment approach. Discordant HER2 status 
between primary and metastatic sites is one possible reason underlying drug resistance to 
HER2-targeted therapy. In gastric cancer, previous reports revealed that discordant HER2 
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status between primary and metastatic sites was observed in 5–20% of patients [34]. However, 
in CRC, this issue has not been investigated fully to date. In this study, we demonstrated that 
1 of the 4 (25%) patients with HER2-positive status at the primary site was HER2-negative at 
the metastatic site, suggesting that HER2 status is not necessarily maintained during the 
metastatic process. In general, tissue samples from the metastatic site may not always be 
available. Future studies, such as targeted sequencing analysis of liquid biopsy samples might 
have the potential to resolve this issue and facilitate precision medicine [35]. 
 
Regarding pros and cons of IHC/FISH and CGS for evaluating HER2 status, we consider that 
IHC/FISH are convenient, widely accepted, and established way to evaluate for breast and 
gastric cancer. However, diagnostic reproducibility may be sometimes problematic; 
especially, because of tumor heterogeneity. Conversely, CGS is expensive compared to 
IHC/FISH, and tested in only specialized laboratories. However, CGS has ability to test 
numerous gene alterations, which are directly associated with treatment strategy, in a single 
assay. We believe that CGS has possibility to facilitate precision medicine. 
 
This study has two potential limitations. First, this was a retrospective study performed at two 
institutions and included a small number of patients. Second, we could not demonstrate an 
association between HER2 amplification detected by CGS and the efficacy of HER2-targeted 
therapy. Future studies should investigate patients with metastatic CRC to determine whether 
HER2-targeted therapy is effective for patients with HER2 amplification detected by CGS. 
 
Conclusion 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
16 
There is a small, distinct category of HER2-positive CRC patients who are candidates for 
HER2-targeted therapy. CGS has the same sensitivity as IHC and FISH for detecting HER2-
positive patients and has the potential to facilitate precision medicine and tailor-made 
treatment. 
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Figure legends 
 
Figure 1. HER2-positive and HER2-negative cases in colorectal cancer 
This case was HER2 IHC 3+ in 100% of cancer cells (A, B, C), and was diagnosed as 
“HER2-positive.” This case was HER2 IHC 3+ in 10% of cancer cells (D, E, F), and was 
diagnosed as “HER2-negative.” 
Hematoxylin and eosin staining, ×1 objective lens (A, D); anti-HER2 staining, ×1 objective 
lens (B, E), ×20 objective lens (C, F). 
 
Figure 2. KRAS codon 12/13 mutation and HER2 amplification in 201 patients 
There were 9 patients with KRAS codon 12/13 wild-type and HER2 amplification, who were 
candidates for HER2-targeted therapy. 
 
Figure 3. A case of concordant HER2 status between primary and metastatic sites 
This concordant case was diagnosed as IHC 3+ in 100% of cancer cells at both the primary 
site (A, B) and bone metastasis (C, D). 
Hematoxylin and eosin staining, ×20 objective lens (A, C); anti-HER2 staining, ×20 objective 
lens (B, D). 
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Table 1. Comparison between HER2 status and HER2 amplification at the 
primary site 
 HER2 status (IHC and FISH) 
 Positive Negative 
HER2 amplification (CGS)   
Positive 10 0 
Negative 0 191 
Abbreviations: HER2, human epidermal growth factor receptor 2; CGS, 
comprehensive genomic sequencing; IHC, immunohistochemistry; FISH, 
fluorescence in situ hybridization. 
n = 201, P < 0.001. 
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Table 2. HER2 status and HER2 amplification/mutation evaluated using CGS 
Case No. Primary site  Metastatic site 
HER2 
status 
IHC (% of 
total area) 
FISH CGS  HER2 
status 
IHC (% of 
total area) 
FISH 
Amplification Mutation  
1 Positive 3+ (100%)  Amplified -     
2 Positive 3+ (100%)  Amplified -     
3 Positive 3+ (100%)  Amplified -  Negative 0  
4 Positive 3+ (100%)  Amplified -     
5 Positive 3+ (100%)  Amplified -     
6 Positive 3+ (100%) Positive Amplified S310Y     
7 Positive 3+ (60%)  Amplified -  Positive 3+ (100%)  
8 Positive 3+ (100%)  Amplified -  Positive 3+ (100%)  
9 Positive 3+ (60%)  Amplified -     
10 Positive 3+ (80%)  Amplified -  Positive 3+ (100%)  
11 Negative 2+ (70%) Negative - R678Q     
12 Negative 0  - V308M     
13 Negative 0  - A879delinsAE     
14 Negative 2+ (80%) Negative - R647K  Negative 0  
15 Negative 0  - R678Q     
Abbreviations: HER2, human epidermal growth factor receptor 2; CGS, comprehensive genomic sequencing; IHC, 
immunohistochemistry; FISH, fluorescence in situ hybridization. 
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Table 3. HER2 status and other clinicopathological characteristics 
 HER2 status  
Variable Positive 
(n = 10) 
Negative 
(n = 191) 
P-value 
Age (years)    
<65 4 96 0.748 
≥65 6 95  
Sex    
Male 7 110 0.526 
Female 3 81  
Location    
Right side 1 55 0.289 
Left side 9 136  
Tumor size (mm)    
<50 5 83 0.751 
≥50 5 108  
T category    
T1, 2 3 21 0.102 
T3, 4 7 170  
Histopathological grading    
G1, 2 7 140 0.730 
G3 3 51  
Lymphatic invasion    
Absence 6 73 0.195 
Presence 4 118  
Venous invasion    
Absence 3 45 0.705 
Presence 7 146  
N category    
N0 3 56 0.999 
N1, 2 7 135  
M category    
M0 3 87 0.517 
M1 7 104  
MLH1/MSH2 status    
Normal 5 86 0.942 
Abnormal 1 18  
Medullary type    
Presence 0 5 0.999 
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Absence 10 186  
Mucinous type    
Presence 0 15 0.999 
Absence 10 176  
Crohn-like lymphoid reaction    
Presence 0 31 0.366 
Absence 10 160  
Tumor infiltrating lymphocytes
a
    
Presence 0 36 0.214 
Absence 10 155  
KRAS codon 12/13    
Wild-type 9 133 0.286 
Mutant 1 58  
NRAS codon 12/13    
Wild-type 10 190 0.999 
Mutant 0 1  
BRAF V600E    
Wild-type 10 179 0.999 
Mutant 0 13  
Abbreviations: HER2, human epidermal growth factor receptor 2. 
a
 Cut-off value = 10 lymphocytes/5 high power fields. 
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Table 4. Comparison of HER2 status between 45 primary sites and 
corresponding metastatic sites 
 HER2 status at metastatic site 
 Positive Negative 
HER2 status at primary site   
Positive 3 1 
Negative 0 41 
Abbreviations: HER2, human epidermal growth factor receptor 2. 
n = 45, P < 0.001. 
 
 
